Developing a radiosensitivity gene signature for Caucasian patients with breast cancer

Ji,Ye; Jiang,Qinghua; Jian,Guohao; Sun,Haitong; Wang,Yamin; Qin,Hualong; Zhang,Shuyu; Cao,Jianping; Tang,Zaixiang

doi:10.3892/or.2018.6567

Developing a radiosensitivity gene signature for Caucasian patients with breast cancer

Authors:
- Ye Ji
- Qinghua Jiang
- Guohao Jian
- Haitong Sun
- Yamin Wang
- Hualong Qin
- Shuyu Zhang
- Jianping Cao
- Zaixiang Tang
View Affiliations

Affiliations: Department of Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Basic Science, Changzhou Vocational Institute of Engineering, Changzhou, Jiangsu 213164, P.R. China, Department of Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Basic Science, Changzhou Vocational Institute of Engineering, Changzhou, Jiangsu 213164, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, School of Radiation Medicine and Protection and Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215006, P.R. China, School of Radiation Medicine and Protection and Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: July 12, 2018 https://doi.org/10.3892/or.2018.6567
Pages: 1695-1705

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adjuvant radiotherapy is an important clinical treatment option for patients with breast cancer. However, for Caucasian patients, the clinical benefit of adjuvant radiotherapy can differ from African‑American patients with respect to the overall survival. The goal of the current study was to develop a gene signature and to pre‑identify patients likely to benefit from radiotherapy. Using publicly available breast cancer data from The Cancer Genome Atlas, a new cross‑validation procedure was proposed for developing a gene signature and predicting radiosensitive patients. The results demonstrated that the predicted radiosensitive patients who received radiotherapy exhibited a significantly better survival, while the effect of radiotherapy was not significant for predicted non‑radiosensitive patients. Further hierarchical cluster analysis revealed that the predicted sensitivity for each patient corresponded closely to the results of the cluster analysis. Collectively, the findings of the current study demonstrated that a radiosensitive molecular signature can be used to identify radiosensitive Caucasian patients with breast cancer.

View Figures

View References

1	American Cancer Society, : Cancer facts and figures 2016. Journal 2016.
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), ; Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378:1707–1716. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wärnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, Ringberg A, Karlsson P, Arnesson LG, Anderson H, et al: Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 32:3613–3618. 2014. View Article : Google Scholar : PubMed/NCBI
5	Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC, Zhang CY, Sun SS and Wu J: Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: A meta-analysis. Oncotarget. 8:28215–28225. 2017.PubMed/NCBI
6	Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, et al: Current controversies in radiotherapy for breast cancer. Radiat Oncol. 12:252017. View Article : Google Scholar : PubMed/NCBI
7	Ahmadloo N, Kadkhodaei B, Omidvari S, Mosalaei A, Ansari M, Nasrollahi H, Hamedi SH and Mohammadianpanah M: Lack of prophylactic effects of aloe vera gel on radiation induced dermatitis in breast cancer patients. Asian Pac J Cancer Prev. 18:1139–1143. 2017.PubMed/NCBI
8	Karlsson P: Postoperative radiotherapy after DCIS: Useful for whom? Breast. 34 Suppl 1:S43–S46. 2017. View Article : Google Scholar : PubMed/NCBI
9	Hirst DG and Robson T: Molecular biology: The key to personalised treatment in radiation oncology? Br J Radiol. 83:723–728. 2010. View Article : Google Scholar : PubMed/NCBI
10	Tsoutsou PG, Durham AD and Vozenin MC: A need for biology-driven personalized radiotherapy in breast cancer. Breast Cancer Res Treat. 167:603–604. 2018. View Article : Google Scholar : PubMed/NCBI
11	Jang BS and Kim IA: A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. Radiother Oncol. 124:403–410. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lai Y, Chen Y, Lin Y and Ye L: Down-regulation of LncRNA CCAT1 enhances radiosensitivity via regulating miR-148b in breast cancer. Cell Biol Int. 42:227–236. 2018. View Article : Google Scholar : PubMed/NCBI
13	Liu G, Wang H, Zhang F, Tian Y, Tian Z, Cai Z, Lim D and Feng Z: The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats. Int J Mol Sci. 18:E10272017. View Article : Google Scholar : PubMed/NCBI
14	Zhang X, Li Y, Wang D and Wei X: miR-22 suppresses tumorigenesis and improves radiosensitivity of breast cancer cells by targeting Sirt1. Biol Res. 50:272017. View Article : Google Scholar : PubMed/NCBI
15	Zhou ZR, Yang ZZ, Wang SJ, Zhang L, Luo JR, Feng Y, Yu XL, Chen XX and Guo XM: The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. Acta Pharmacol Sin. 38:513–523. 2017. View Article : Google Scholar : PubMed/NCBI
16	Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et al: Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, −224, −132 and let7g. Radiother Oncol. 108:451–457. 2013. View Article : Google Scholar : PubMed/NCBI
17	Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Fränk M, Scharf JG, Burfeind P, Becker H, Beissbarth T, Ghadimi BM, et al: A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys. 78:1184–1192. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hall JS, Iype R, Senra J, Taylor J, Armenoult L, Oguejiofor K, Li Y, Stratford I, Stern PL, O'Connor MJ, et al: Investigation of radiosensitivity gene signatures in cancer cell lines. PLoS One. 9:e863292014. View Article : Google Scholar : PubMed/NCBI
19	Pramana J, Van den Brekel MW, van Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, Atsma D, Pimentel N, Hoebers FJ, Rasch CR, et al: Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys. 69:1544–1552. 2007. View Article : Google Scholar : PubMed/NCBI
20	Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, et al: Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther. 10:1019–1026. 2010. View Article : Google Scholar : PubMed/NCBI
21	Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH, Harris EE, et al: Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res. 18:5134–5143. 2012. View Article : Google Scholar : PubMed/NCBI
22	Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ and Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 355:560–569. 2006. View Article : Google Scholar : PubMed/NCBI
23	Freidlin B, Jiang W and Simon R: The cross-validated adaptive signature design. Clin Cancer Res. 16:691–698. 2010. View Article : Google Scholar : PubMed/NCBI
24	Freidlin B and Simon R: Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 11:7872–7878. 2005. View Article : Google Scholar : PubMed/NCBI
25	Tang Z, Zeng Q, Li Y, Zhang X, Ma J, Suto MJ, Xu B and Yi N: Development of a radiosensitivity gene signature for patients with soft tissue sarcoma. Oncotarget. 8:27428–27439. 2017.PubMed/NCBI
26	Zhu Y, Qiu P and Ji Y: TCGA-assembler: Open-source software for retrieving and processing TCGA data. Nat Methods. 11:599–600. 2014. View Article : Google Scholar : PubMed/NCBI
27	Molinaro AM, Simon R and Pfeiffer RM: Prediction error estimation: A comparison of resampling methods. Bioinformatics. 21:3301–3307. 2005. View Article : Google Scholar : PubMed/NCBI
28	Simon R, Radmacher MD, Dobbin K and McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 95:14–18. 2003. View Article : Google Scholar : PubMed/NCBI
29	Grandi A, Santi A, Campagnoli S, Parri M, De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S, Sarmientos P, et al: ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. Oncotarget. 7:63596–63610. 2016. View Article : Google Scholar : PubMed/NCBI
30	Mulvihill MM, Benjamin DI, Ji X, Le Scolan E, Louie SM, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, et al: Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chem Biol. 21:831–840. 2014. View Article : Google Scholar : PubMed/NCBI
31	Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw J, et al: Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia. 30:2322–2331. 2016. View Article : Google Scholar : PubMed/NCBI
32	Jiang Z, Song Q, Zeng R, Li J, Li J, Lin X, Chen X, Zhang J and Zheng Y: MicroRNA-218 inhibits EMT, migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer. Oncotarget. 7:45622–45636. 2016.PubMed/NCBI
33	Zhai JS, Song JG, Zhu CH, Wu K, Yao Y and Li N: Expression of APPL1 is correlated with clinicopathologic characteristics and poor prognosis in patients with gastric cancer. Curr Oncol. 23:e95–e101. 2016. View Article : Google Scholar : PubMed/NCBI
34	Liu Y, Zhang C, Zhao L, Du N, Hou N, Song T and Huang C: APPL1 promotes the migration of gastric cancer cells by regulating Akt2 phosphorylation. Int J Oncol. 51:1343–1351. 2017. View Article : Google Scholar : PubMed/NCBI
35	Zhou J, Wu X, Li G, Gao X, Zhai M, Chen W, Hu H and Tang Z: Prediction of radiosensitive patients with gastric cancer by developing gene signature. Int J Oncol. 51:1067–1076. 2017. View Article : Google Scholar : PubMed/NCBI
36	Tang Z, Zeng Q, Li Y, Zhang X, Suto MJ, Xu B and Yi N: Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signature. Oncol Rep. 38:2814–2824. 2017. View Article : Google Scholar : PubMed/NCBI